anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Rationale: Previous studies investigating the impact of comorbidities on the effectiveness of biologic agents have been relatively small and of short duration and have not compared classes of biologic agents. Objectives: To determine the association between type 2-related comorbidities and biologic agent effectiveness in adults with severe asthma (SA). Methods: This cohort study used International Severe Asthma Registry data from 21 countries (2017-2022) to quantify changes in four outcomes before and after biologic therapy-annual asthma exacerbation rate, FEV1% predicted, asthma control, and long-term oral corticosteroid daily dose-in patients with or without allergic rhinitis, chronic rhinosinusitis (CRS) with or without nasal polyps (NPs), NPs, or eczema/atopic dermatitis. Measurements and Main Results: Of 1,765 patients, 1,257, 421, and 87 initiated anti-IL-5/5 receptor, anti-IgE, and anti-IL-4/13 therapies, respectively. In general, pre- versus post-biologic therapy improvements were noted in all four asthma outcomes assessed, irrespective of comorbidity status. However, patients with comorbid CRS with or without NPs experienced 23% fewer exacerbations per year (95% CI, 10-35%; P < 0.001) and had 59% higher odds of better post-biologic therapy asthma control (95% CI, 26-102%; P < 0.001) than those without CRS with or without NPs. Similar estimates were noted for those with comorbid NPs: 22% fewer exacerbations and 56% higher odds of better post-biologic therapy control. Patients with SA and CRS with or without NPs had an additional FEV1% predicted improvement of 3.2% (95% CI, 1.0-5.3; P = 0.004), a trend that was also noted in those with comorbid NPs. The presence of allergic rhinitis or atopic dermatitis was not associated with post-biologic therapy effect for any outcome assessed. Conclusions: These findings highlight the importance of systematic comorbidity evaluation. The presence of CRS with or without NPs or NPs alone may be considered a predictor of the effectiveness of biologic agents in patients with SA.
SEGLENTIS is a co-crystal that contains tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re-uptake, and celecoxib, a nonsteroidal anti-inflammatory drug, in a 1:1 molecular ratio.

Tramadol

Although the mode of action of tramadol is not completely understood, the analgesic effect of tramadol is believed to be due to both binding to µ-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin.

Opioid activity of tramadol is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to µ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in µ-opioid binding. Tramadol-induced analgesia is only partially antagonized by the opiate antagonist naloxone in several animal tests. The relative contribution of both tramadol and M1 to human analgesia is dependent upon the plasma concentrations of each compound [see Clinical Pharmacology (12.2)].

Celecoxib

Celecoxib is an analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of cyclooxygenase-2 (COX-2).

Celecoxib is a potent inhibitor of prostaglandin synthesis in vitro. Celecoxib concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
This is a two-arm, parallel randomized controlled trial with a 12 weeks treatment duration and long-term 52 weeks follow-up. Outpatient, and walk-in clinics, and advertising will be used to recruit participants from the general population. Individual counselling regarding smoking cessation will be provided to the participants using EC as well as nicotine patches. Participants included must be at least of legal age allowed for smoking in the country, of either gender, regular smokers (minimum 10 cigarettes/day for at least a year) and interested to stop smoking. Participants will be scheduled for a screening visit and a baseline (BL) visit at the trial site. The participants will be scheduled for eight study visits in total, including five treatment sessions and three follow-up visits, using both face to face interaction at trial site as well as follow up on telephone. Eight study visits are planned at weeks 1, 2, 4, 8, 12, 18, 24, and 52. Exhaled carbon monoxide assessment will be used at the trial site to quantify biochemically validated smoking abstinence (exhaled carbon monoxide levels above ten ppm regarded as indicator of current smoking). All secondary outcomes and self-reported usage of nicotine patches, EC and cigarettes will be monitored throughout the study. Information about self-reported smoking, usage of EC and nicotine patches, use of other smoking cessation therapy and side effects will be gathered at all follow-up calls and visits.
1317400 Medicinal pellets SUMITOMO CHEMICAL CO Ltd 15 June 1971 [15 June 1970 10 Dec 1970] 28008/71 Heading A5B [Also in Division B5] Pellets are formed from powders by adding binder liquid to granules and sprinkling these wet nuclear granules, onto the powders, the granules consisting of at least one of synthetic colloidal silicon dioxide, synthetic silicate of aluminium or magnesium, aluminium hydroxide gel, aluminium hydroxide-magnesium hydroxide gel, aluminium hydroxide-aluminium carbonate gel, or magnesium aluminium hydroxide carbonate. The binder liquid may be water or an alcohol, and the powders may be for medical purposes, several examples being given. Known processes - and apparatus are used, e.g. the granules, which should be shaped and sized appropriately for the desired shape of pellet, may be placed in a vessel, binder liquid added and stirred then left standing and finally screened and blended. The powder is then put into a dish-type pelletizer and the wet granules sprinkled thereon by a vibration feeder during rotation of the pelletizer, rolling is continued for a period and the formed pellets are then dried and screened. The powder may be, or contain, a drum or adjuvant, and may also contain a surfactant, lubricant, binder, pH-adjusting agent, tastemasking agent, flavouring or colouring agent.
1. Method for inducing onset of the reproductive cycle of sows after the end of a preceding cycle recovery or inhibition, characterized in that the animals are injected with an injection solution that contains synthetically produced FSH-releasing hormones as a biologically active substance with known sequences consisting of 10 amino acids (decapeptide). 2. Method according to claim 1, characterized in that the FSH-releasing hormone has the amino acid sequence Pyr-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2. 3. Method according to claim 1 and 2, characterized in that the amino acid sequence is modified by the addition of further components. 4. Method according to at least one of the preceding claims, characterized in that the active substance is injected 0 to 96 hours, preferably 12 to 48 hours, and, more particularly, 24 hours after the end of a preceding cycle recovery or inhibition or a biotechnical pretreatment. 5. Method according to at least one of the preceding claims, characterized in that injection solutions with a content from 5 to 500 mlg, preferably 50 to 300 mlg and, more particularly, 100 to 200 mlg of active substance per milliliter of injection solution are used. 6. Method according to at least one of the preceding claims, characterized in that the injection solution administered per individual animal contains 25 to 500 mlg, preferably 50 to 300 mlg and, more particularly, 100 to 200 mlg of active substance. 7. Method according to at least one of the preceding claims, characterized in that at an interval of 72 hours after the injection for the cycle induction, an ovulation-triggering injection takes place with the active substance D-Phe 6 Gonadorelin.
<P>PROBLEM TO BE SOLVED: To provide a method for producing a compound for generating hydrogen gas and having weak adverse effects.  <P>SOLUTION: This method for producing the compound for generating the hydrogen gas includes the step of fermenting the fruits of Hippophae rhamnoides and the powder of Crepidiastrum lonceolatum by lactobacillus. Here, the compound for forming the hydrogen gas consists of the one molecule of resveratrol, two molecules of gallic acid and one molecule of magnesium, and the carboxyl group of the one molecule of gallic acid is bonded to the hydroxy group of two phenolic hydroxy groups of the resveratrol through ester linkage. The method of the production includes adding 0.01 to 0.09 pt.wt. of powder of Crepidiastrum lonceolatum, and 0.004 to 0.01 pt.wt. of lactobacillus with respect to 1 pt.wt. of rhamnoides fruits, heated to 34 to 48°C and fermented for 24 to 98 hr, and further, the obtained compound for forming the hydrogen gas can be applied in the fields of pharmaceuticals, foods and cosmetics.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention discloses a lobed kudzuvine root protein and a preparation method of nanoparticles of the lobed kudzuvine root protein. The lobed kudzuvine root protein with the sequence of DFVYDMCGNVLN is obtained by extraction with a Tris-HCl buffer solution, graded sedimentation with ethanol and ion exchange chromatographic separation. The nanoparticles of the lobed kudzuvine root protein are prepared by heating a water solution of the lobed kudzuvine root protein at the temperature of 100 DEG C for 60 min under the conditions that the protein concentration is 1 mg/mL and the pH is 6.05, and the nanoparticles of the lobed kudzuvine root protein show relatively low cytotoxicity in vitro. A lyophilized product of the nanoparticles of the lobed kudzuvine root protein has excellent flowability and is easy to store stably. The lobed kudzuvine root protein disclosed by the invention is from foods and has high safety. According to the preparation method of the nanoparticles, no crosslinking agent is not used, finished products widely exist in various decoctions using lobed kudzuvine root, and the nanoparticles can be taken by the majority of people for many years and have high safety. The nanoparticles of the lobed kudzuvine root protein disclosed by the invention are expected to be applied to in vivo delivery of a variety of medicaments.
Xenon, an inert gas commonly used in medicine, has been considered as a potential option for prolonged preservation of donor packed red blood cells (pRBCs) under hypoxic conditions. This study aimed to investigate how xenon affects erythrocyte parameters under prolonged storage. In vitro model experiments were performed using two methods to create hypoxic conditions. In the first method, xenon was introduced into bags of pRBCs which were then stored for 42 days, while in the second method, xenon was added to samples in glass tubes. The results of our experiment showed that the presence of xenon resulted in notable alterations in erythrocyte morphology, similar to those observed under standard storage conditions. For pRBC bags, hemolysis during storage with xenon exceeded the acceptable limit by a factor of six, whereas the closed-glass-tube experiment showed minimal hemolysis in samples exposed to xenon. Notably, the production of deoxyhemoglobin was specific to xenon exposure in both cell suspension and hemolysate. However, this study did not provide evidence for the purported protective properties of xenon.
For the first part of the study, participants will be either people with type 1 diabetes treated with insulin pump therapy or volunteers without diabetes. The 2 groups will be matched as far as possible by age, body mass index and usual level of activity. Participants will attend an exercise laboratory on 2 occasions. On the first occasion, which can take place at any time of day, formal written consent will be obtained for participation in the study. Participants will then undergo measurement of maximal exercise capacity (VO2 MAX). On the second occasion they will attend 2 hours after a lunch containing 60 grams of carbohydrate (advice will be given on how this can be achieved). A cannula will be inserted on arrival and blood samples obtained. Arterialised samples will be obtained by using a heated hand technique. Once the cannula has been inserted participants with type 1 diabetes will be asked to reduce the basal insulin infusion rate on their insulin pump to 70% of normal until the end of the study visit. After 30 minutes a further set of blood samples will be obtained, and participants will then start to exercise for 1 hour at 50% VO2 MAX. A further set of blood samples will be obtained at the end of the hour of exercise. Participants will then rest for 30 minutes before a final set of blood samples is taken. At this point the cannula will be removed and the study visit ends. Participants with diabetes will be given the choice to return basal insulin infusion rate to normal at this point. A snack will be offered.

Blood glucose will be monitored every 10 minutes and also if a participant feels symptoms of hypoglycaemia. If hypoglycaemia occurs the protocol will be stopped and carbohydrate given until the blood glucose level returns to the normal range.
In the Home Grocery Delivery arm, each participant will receive home grocery delivery from PeaPod grocery delivery service or from FreshDirect (depending on the participant"s zip code), worth $128 per month, for the duration of study participation (6 months). Patients in the Delivery arm will review a list of food categories and a subset of items in each category with a COA.
The present invention provides a copolymer able to be used as an oily gelling agent capable of preparing a stable oily gel-like composition. This copolymer is characterized by containing a hydrophobic monomer represented by general formula (1) and a hydrophilic monomer represented by general formula (2) and /or general formula (3). (In formula (1), R 1  is a straight chain or branched chain alkyl group having 16-22 carbon atoms. R 2  is a hydrogen atom or a methyl group.) (In formula (2), R 3  is a hydrogen atom, a glyceryl group, a straight chain or branched chain hydroxyalkyl group having 1-4 carbon atoms, or a poly(propylene glycol) group represented by -(C 3 H 6 O) n H (here, n is an integer between 2 and 10). R 4  is a hydrogen atom or a methyl group.) (In formula (3), R 5  is a hydrogen atom or a methyl group. R 6  is a straight chain or branched chain alkyl group or hydroxylalkyl group having 1-4 carbon atoms, or a substituent group represented by general formula (4).)
The patients in this group will not receive scalp nerve block. The patients will be given dexmedetomidine intravenously at a rate of 0.4 μg/kg/h from skin incision until the beginning of dura mater closure, and will be adjusted to 0.05 μg/kg/h for 48 hours after surgery.
Substance Use Disorders (SUDs) present a significant challenge to global public health, with prolonged drug use not only impairing individual health but also hindering social development. Despite various interventions aimed at addressing drug abuse and dependence, a high relapse rate remains a prominent issue. In light of this, this study aims to explore the impact of perceived stress on the relapse of individuals with SUDs, as well as the mediating role of self-control and the moderating role of social support, in hopes of providing new perspectives for interventions to reduce the risk of relapse among individuals with SUDs. By utilizing a convenience sampling method, 420 male individuals with SUDs were recruited from detoxification centers in Guangxi, China. They completed questionnaires on perceived stress, self-control, social support, and tendencies towards relapse. A total of 401 valid datasets were obtained and analyzed using the SPSS Process plugin to conduct a moderated mediation model analysis. Results: (1) Perceived stress had a positive impact on the relapse of individuals with SUDs, (2) Self-control played a partial mediating role between perceived stress and the relapse, (3) The direct effect of perceived stress on the relapse and its first half of the indirect effect were moderated by social support. The research emphasize the critical importance of learning stress management strategies, enhancing self-control, and receiving comprehensive social support in the prevention and treatment of substance dependence. By strengthening self-control and social support as both internal and external resources, the likelihood of relapse among individuals with SUDs can be reduced, contributing to more effective and comprehensive drug rehabilitation strategies.
Decreases in clearance and protein binding, and increases in volume of distribution and half-life has been reported in patients with cirrhosis. In such patients, a 2- to 5- fold increase in mean half-life has been reported. Delayed elimination has also been reported for the active metabolite desmethyldiazepam. Benzodiazepines are commonly implicated in hepatic encephalopathy. Increases in half-life have also been reported in hepatic fibrosis and in both acute and chronic hepatitis (see ).  CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations:Hepatic Insufficiency
Neutrophils present the host's first line of defense against bacterial infections. These immune effector cells are mobilized rapidly to destroy invading pathogens by (a) reactive oxygen species (ROS)-mediated oxidative bursts and (b) via phagocytosis. In addition, their antimicrobial service is capped via a distinct cell death mechanism, by the release of their own decondensed nuclear DNA, supplemented with a variety of embedded proteins and enzymes. The extracellular DNA meshwork ensnares the pathogenic bacteria and neutralizes them. Such neutrophil extracellular DNA traps (NETs) have the potential to trigger a hemostatic response to pathogenic infections. The web-like chromatin serves as a prothrombotic scaffold for platelet adhesion and activation. What is less obvious is that platelets can also be involved during the initial release of NETs, forming heterotypic interactions with neutrophils and facilitating their responses to pathogens. Together, the platelet and neutrophil responses can effectively localize an infection until it is cleared. However, not all microbial infections are easily cleared. Certain pathogenic organisms may trigger dysregulated platelet-neutrophil interactions, with a potential to subsequently propagate thromboinflammatory processes. These may also include the release of some NETs. Therefore, in order to make rational intervention easier, further elucidation of platelet, neutrophil, and pathogen interactions is still needed.
Patients of this arm will be selected for liver transplantation for alcoholic cirrhosis using an abstinence period of 6 months. Outcome of these patients will be compared to that of patients transplanted for severe alcoholic hepatitis.
Painful small fiber sensory neuropathy (SFN) is relatively common and a disabling medical condition. It is the most common type of painful sensory neuropathy in patients older than 50 years of age. It is defined as a neuropathy that exclusively or predominantly affects the A-δ (small myelinated) and nociceptive C (unmyelinated) nerve fibers and their functions. The neuropathic pain associated with SFN is described by the patients as burning ("feet are on fire"), sharp ("knife-like, jabbing or pins and needles"), shooting, and aching pain in the toes and feet. The feet are described as tingling, numb, or feeling tight, wooden or dead. The pain is disabling and often exacerbated at night interfering and disrupting the sleep pattern. Allodynia and cramps may also occur. Some patients also describe pressure induced pain in their feet with standing and walking. The autonomic nerves may be involved leading to increased or decreased sweating, facial flushing, skin discoloration and erectile dysfunction in up to 40% of males. On examination there is a dramatic mismatch between the symptoms and observable deficits in SFN. Only abnormal findings are the loss of pinprick and temperature sensations in feet that may extend up to the knees. Touch sensation may be diminished but other sensations are usually preserved. By definition, patients with SFN are allowed to have minor involvement of large fibers distally with reduced vibration in toes but the ankle reflexes are usually preserved.

This study will be of a crossover design thus minimizing the number of subjects needed. Each patient will act as his/her own control. Previous studies of pregabalin have shown that the desired effect is achieved by eight weeks of treatment. Therefore each patient will start on either placebo or pregabalin. They will be assessed on this treatment arm for eight weeks. There will be a two-week drug tapering and washout period before switching treatments, followed by re-assessment for an additional eight weeks. This design minimizes the amount of time that the patient will be treated with placebo.
FIELD: medical engineering. SUBSTANCE: device has nucleus containing therapeutically active agent and membrane coating the nucleus. The membrane is manufactured from an elastomer. Elastomer on siloxane base containing 3,3,3-trifluoropropyl groups attached to Si-atoms of siloxane links is proposed. The device has small cross-section to allow one easily introducing it and injecting the therapeutically active agent. EFFECT: constant delivery rate within prolonged time period. 12 cl, 2 dwg
An unexpected postural perturbration is a major risk factor of falls and injuries during gait. A postural perturbration is a sudden change in conditions that displaces the body posture away from equilibrium. Reactive postural control response is an immediate ( 70-120 ms ) automatic "like reflex" response which is initiated by unexpected postural perturbration in order to maintain balance. Even among young healthy adults there could be a problem in balance performance which does not become evident untill a slip or a trip or any other sudden perturbration happens. Thus a simple test of pertubration while standing or walking can identify a problem .

This study is comparing the reactive postural control of physical education students who suffer from chronic ankle instability (CAI) to healthy students on a Perturbation Treadmill. The device consists of a treadmill mounted on a moving force plate platform. The platform moves in the medial/ lateral plains to simulate a slip and a trip in both the standing and walking phase. Their reactive postural control is tested in a few conditions: standing on both legs - eyes open and eyes closed, in tandem standing, standing on one leg and in walking. In each condition the perturbration is given every 5-15 seconds in different speed and in unexpected direction (right /left). Lost of balance control is any change in the original location of the foot in standing conditions or stepping out of the treadmill.
Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 8 mg once daily (QD) in the acute treatment period from Week 1-6 followed by MK-8189 8 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12. Enrollment of participants in the MK-8189 8 mg arm was closed with Amendment 4. Participants enrolled before Amendment 4 that have been assigned to 8 mg MK-8189 will remain on 8 mg MK-8189 per protocol.
Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (30mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.